Business Engine Forms Pharmaceutical Advisory Board; Names Dr. Kenneth Kaitin, PhD, As Chairman To Refine Direction of Global R&D Project & Resource Management Application.Business Editors/High-Tech Writers SAN FRANCISCO--(BUSINESS WIRE)--April 10, 2001 Business Engine(R), a leading provider of project and resource collaboration solutions, today announced the creation of the Business Engine Pharmaceutical Advisory Board, and named Dr. Kenneth Kaitin, PhD, as its chairman. The Board has been formed to identify common resource and project management challenges faced by the pharmaceutical and biotech industries. Its recommendations will help Business Engine further customize its Web-based pharmaceutical applications, which empower global R&D project leaders to more efficiently manage their three most precious resources: people, time, and money. On average, only five of every 5,000 drugs tested make it to market. And with only three out of ten approved drugs recovering average R&D costs, pharmaceutical companies are under increasing pressure to identify which drugs will be successful, and to cost-efficiently expedite delivery of those drugs to market. "Global research and development teams today face enormous challenges managing their resources across organizational boundaries, international borders, and multiple time zones," said Dr. Kenneth Kaitin, Ph.D., director, Tufts Center for the Study of Drug Development, and chairman of the Business Engine Pharmaceutical Advisory Board. "Business Engine's Pharmaceutical Advisory Board will play a key role in shaping the development of Web-based applications that provide leaders of global pharmaceutical development programs with full visibility and control of their internal, outsourced, and third party resources. This improved visibility and control will allow pharmaceutical firms to focus on the most promising programs, avoid critical resource bottlenecks, and bring new and improved products to market, faster, and at lower cost," added Kaitin. Dr. Kaitin is a respected member within the pharmaceutical field and currently serves as director of the Tufts Center for the Study of Drug Development. As chairman, he will be responsible for assembling a voluntary team of experts to sit on the Board. "We're very pleased that Dr. Kaitin will be leading this new Board. His contribution will help to ensure that we'll advance the development of our existing pharmaceutical software applications to meet the urgent and specific needs of global R&D project teams," said John O'Neil
John O'Neil was born in Kansas City, Missouri in 1915. , chairman and chief executive officer of Business Engine. The formation of the Pharmaceutical Advisory Board extends a similar program designed for the financial services The examples and perspective in this article or section may not represent a worldwide view of the subject. Please [ improve this article] or discuss the issue on the talk page. industry, established less than a year ago. "This kind of emersion e·mer·sion n. The act of emerging; emergence. [From Latin  mersus, past participle of works well for Business Engine and enables us to execute on our plan to target key industries that can benefit from enterprise level collaboration and integrated resource management applications," added O'Neil. Dr. Kenneth Kaitin, PhD. Dr. Kenneth Kaitin, PhD, is the Director of the Tufts Center for the Study of Drug Development at Tufts University Tufts University, main campus at Medford, Mass.; coeducational; chartered 1852 by Universalists as a college for men. It became a university in 1955. Jackson College, formerly a coordinate undergraduate college for women, merged with the College of Liberal Arts in , where he studies national and worldwide trends in pharmaceutical innovation, regulation, and public policy. He is also Assistant Professor of Pharmacology and Experimental Therapeutics at Tufts University School of Medicine The Tufts University School of Medicine is one of the eight schools that comprise Tufts University. Located on the university's health sciences campus in the Chinatown district of Boston, Massachusetts, the medical school has clinical affiliations with thousands of doctors and . Dr. Kaitin has written extensively on factors that contribute to the slow pace and high cost of pharmaceutical R&D, and the impact of regulatory and legislative initiatives to speed drug development and approval. His articles have been published widely in medical and policy journals. Dr. Kaitin has provided testimony before the U.S. Congress in hearings on FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. reform, and he has worked closely with the U.S. Council on Competitiveness in the preparation of their report on the pharmaceutical industry. He is a former President of the Drug Information Association, and he serves on the faculty of the European Center for Pharmaceutical Medicine. He is a member of the American Society for Clinical Pharmacology Clinical pharmacology is the science of drugs and their clinical use. It is underpinned by the basic science of pharmacology, with added focus on the application of pharmacological principles and methods in the real world. and Therapeutics, the New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of Pharma Forum, the Drug Information Association, and Regulatory Affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: About Business Engine Based in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden , Ca., Business Engine has provided resource management, project portfolio management and team collaboration solutions that enhance the effectiveness of development teams for project-driven organizations since 1987. Today, Business Engine's platform-independent, Internet-based solutions scale easily to meet the needs of the resource-constrained organizations and the globally-sourced marketplace. Its pharmaceutical customers include Aventis, Lilly, Merck, Pfizer, Pharmacia, and Roche. Privately held, key Business Engine investors include Broadview Capital Partners, Morgan Stanley  To comply with Wikipedia's , the introduction of this article needs a complete rewrite. Dean Witter Private Equity, Oak Investment Partners, and DB Capital Partners. For more information on Business Engine, please visit the company's Web site at http://www.businessengine.com.
|
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion